8-K: Silo Pharma Submits Pre-IND Application to FDA for PTSD Treatment SPC-15

Silo Pharma has submitted a pre-Investigational New Drug application to the FDA for its intranasal PTSD treatment, SPC-15, marking a significant step in its clinical development.

Summary

• Silo Pharma has submitted a pre-Investigational New Drug (pre-IND) application to the FDA for SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety.
• Pre-clinical data suggests SPC-15 has additive benefits in combating stress-induced issues at both behavioral and neural levels.
• A non-GLP small animal dose-ranging study completed in February 2024 showed effective and consistent exposure from intranasal administration of SPC-15.
• Silo expects to finalize an exclusive license agreement with Columbia University for SPC-15 in the first half of 2024.
• The company plans to conduct a progressive intellectual and neurological deterioration (PIND) study and a GLP study in the second half of 2024, which are required before submitting an Investigational New Drug (IND) application.
• SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist designed to increase stress resilience, differing from the two currently approved PTSD drugs that primarily target depression.
• Silo Pharma is also developing other treatments including SP-26, a time-release ketamine implant for chronic pain, and SPC-14 and SPU-16 for Alzheimer's and multiple sclerosis respectively.

Sentiment

Score: 7

Explanation: The document is positive due to the progress in the development of SPC-15 and the submission of the pre-IND application. However, it is still early in the development process and there are risks associated with clinical trials and regulatory approval.

Positives

• The submission of the pre-IND application is a key milestone for the development of SPC-15.
• Pre-clinical data suggests SPC-15 has a novel mechanism of action that could provide a differentiated treatment option for PTSD.
• The company has a clear roadmap for the clinical development of SPC-15, including planned PIND and GLP studies.
• The exclusive license agreement with Columbia University will provide Silo with the rights to further develop and commercialize SPC-15.
• The potential for SPC-15 to qualify for the FDA's streamlined 505(b)(2) regulatory pathway could expedite its approval.

Negatives

• The company is still in the pre-clinical stage of development for SPC-15, and there is no guarantee that it will be successful in clinical trials.
• The company is dependent on the exclusive license agreement with Columbia University, which has not yet been finalized.
• The company is a developmental stage biopharmaceutical company and may face challenges in raising capital to fund its research and development activities.
• The company is subject to regulatory risks associated with the development and approval of new drugs.

Risks

• The success of SPC-15 is dependent on positive results from future clinical trials.
• The company may face challenges in securing regulatory approval for SPC-15.
• The company's financial position may be impacted by the costs associated with research and development.
• There is competition from other companies developing treatments for PTSD and anxiety.
• The company's ability to commercialize SPC-15 is dependent on securing necessary funding and partnerships.

Future Outlook

Silo Pharma anticipates that the pre-IND submission will lead to valuable guidance from the FDA as they prepare for the first-in-human clinical trial of SPC-15 in PTSD. The company plans to conduct PIND and GLP studies in the second half of 2024.

Management Comments

• Silo CEO Eric Weisblum commented, 'We believe our preclinical work on SPC-15, supported by published preclinical data, provides a strong foundation for our development strategies and initial clinical trial design.'
• Eric Weisblum also stated, 'We anticipate that our pre-IND submission will lead to valuable guidance from the FDA as we prepare for the first-in-human clinical trial of SPC-15 in PTSD.'

Industry Context

The announcement is significant as it highlights Silo Pharma's progress in developing a novel treatment for PTSD, a condition with limited effective therapies. The focus on a differentiated mechanism of action, increasing stress resilience, sets it apart from existing treatments that primarily target depression. This aligns with the industry's growing interest in innovative approaches to mental health treatments.

Comparison to Industry Standards

• The current standard of care for PTSD includes only two FDA-approved drugs, both of which primarily target the depressive symptoms of the condition, such as Zoloft and Paxil.
• Silo Pharma's SPC-15, with its focus on increasing stress resilience through a novel 5-HT4 receptor agonist mechanism, represents a different approach compared to these existing treatments.
• Other companies are also exploring novel treatments for PTSD, including psychedelic-assisted therapies and other pharmacological interventions, but Silo's intranasal delivery method and focus on stress resilience are unique.
• The company's collaboration with Columbia University is similar to other biotech companies that partner with academic institutions to advance research and development.

Stakeholder Impact

• Shareholders may view the pre-IND submission positively, as it represents progress in the development of a potential new treatment.
• Employees may be motivated by the company's progress and the potential to make a positive impact on patients.
• Patients with PTSD and anxiety may benefit from the development of a new treatment option.
• Columbia University will benefit from the potential commercialization of SPC-15 through the exclusive license agreement.

Next Steps

• Silo Pharma will finalize and enter into an exclusive license agreement with Columbia University in the first half of 2024.
• The company will commence a progressive intellectual and neurological deterioration (PIND) study and a GLP study in the second half of 2024.
• Silo Pharma will submit an Investigational New Drug (IND) application to the FDA after completing the PIND and GLP studies.

Key Dates

Keywords

SPC-15, PTSD, anxiety, pre-IND, FDA, intranasal, clinical trials, biopharmaceutical, serotonin 4 receptor agonist, Columbia University